메뉴 건너뛰기




Volumn 77, Issue 1, 1996, Pages 89-96

Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma

Author keywords

infusion schedule; interleukin 2; metastatic melanoma; toxicity reduction

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

EID: 0030030641     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960101)77:1<89::AID-CNCR15>3.0.CO;2-4     Document Type: Article
Times cited : (69)

References (25)
  • 1
    • 0022349817 scopus 로고
    • Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
    • Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
    • (1985) N Engl J Med , vol.313 , pp. 1485-1492
    • Rosenberg, S.A.1    Lotze, M.T.2    Muul, L.M.3    Leitman, S.4    Chang, A.E.5    Ettinghausen, S.E.6
  • 2
    • 0023115642 scopus 로고
    • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
    • Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
    • (1987) N Engl J Med , vol.316 , pp. 889-897
    • Rosenberg, S.A.1    Lotze, M.T.2    Muul, L.M.3    Chang, A.E.4    Avis, F.P.5    Leitman, S.6
  • 4
    • 0023926926 scopus 로고
    • Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation
    • Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988;6:669-78.
    • (1988) J Clin Oncol , vol.6 , pp. 669-678
    • Thompson, J.A.1    Lee, D.J.2    Lindgren, C.G.3    Benz, L.A.4    Collins, C.5    Levitt, D.6
  • 5
    • 0025241161 scopus 로고
    • Interleukin-2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin-2 and a continuous infusion interleukin 2 regimen
    • Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, et al. Interleukin-2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin-2 and a continuous infusion interleukin 2 regimen. Cancer Res 1990;50:7343-50.
    • (1990) Cancer Res , vol.50 , pp. 7343-7350
    • Clark, J.W.1    Smith, J.W.2    Steis, R.G.3    Urba, W.J.4    Crum, E.5    Miller, R.6
  • 6
    • 0023890374 scopus 로고
    • Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer
    • Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, et al. Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561-67.
    • (1988) Cancer Res , vol.48 , pp. 2561-2567
    • Sondel, P.M.1    Kohler, P.C.2    Hank, J.A.3    Moore, K.H.4    Rosenthal, N.S.5    Sosman, J.A.6
  • 7
    • 0028106484 scopus 로고
    • Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report
    • Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-76.
    • (1994) J Clin Oncol , vol.12 , pp. 1572-1576
    • Yang, J.C.1    Topalian, S.L.2    Parkinson, D.3    Schwartzentruber, D.J.4    Weber, J.S.5    Ettinghausen, S.E.6
  • 8
    • 0024544021 scopus 로고
    • A Phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma
    • Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, et al. A Phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989;7:477-85.
    • (1989) J Clin Oncol , vol.7 , pp. 477-485
    • Dutcher, J.P.1    Creekmore, S.2    Weiss, G.R.3    Margolin, K.4    Markowitz, A.B.5    Roper, M.6
  • 9
    • 0028266553 scopus 로고
    • Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2
    • Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-13.
    • (1994) JAMA , vol.271 , pp. 907-913
    • Rosenberg, S.A.1    Yang, J.C.2    Topalian, S.L.3    Schwartzentruber, D.J.4    Weber, J.S.5    Parkinson, D.R.6
  • 10
    • 0027529476 scopus 로고
    • Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
    • Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
    • (1993) J Natl Cancer Inst , vol.85 , pp. 622-632
    • Rosenberg, S.A.1    Lotze, M.T.2    Yang, J.C.3    Topalian, S.L.4    Chang, A.E.5    Schwartzentruber, D.J.6
  • 11
    • 0027524697 scopus 로고
    • Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
    • Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, et al. Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993;11:1969-77.
    • (1993) J Clin Oncol , vol.11 , pp. 1969-1977
    • Sparano, J.A.1    Fisher, R.I.2    Sunderland, M.3    Margolin, K.4    Ernest, M.L.5    Sznol, M.6
  • 13
    • 0023868863 scopus 로고
    • Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma
    • Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988;6:409-24.
    • (1988) J Clin Oncol , vol.6 , pp. 409-424
    • Mitchell, M.S.1    Kempf, R.A.2    Harel, W.3    Shau, H.4    Boswell, W.D.5    Lind, S.6
  • 14
    • 0002027157 scopus 로고
    • The modified group C experience - Phase III randomized trials of IL-2 vs IL-2/ LAK in advanced renal cell carcinoma and advanced melanoma
    • abstr 714
    • McCabe MS, Stablein D, Hawkins MJ: The modified group C experience - phase III randomized trials of IL-2 vs IL-2/ LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 1991;10:213; (abstr 714).
    • (1991) Proc Am Soc Clin Oncol , vol.10 , pp. 213
    • McCabe, M.S.1    Stablein, D.2    Hawkins, M.J.3
  • 15
    • 0025947455 scopus 로고
    • Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest oncology group study
    • Whitehead RP, Kopecky KJ, Samson MK, Costanzi JJ, Natale RB, Feun LG, et al. Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: southwest oncology group study. J Natl Cancer Inst 1991;83:1250-52.
    • (1991) J Natl Cancer Inst , vol.83 , pp. 1250-1252
    • Whitehead, R.P.1    Kopecky, K.J.2    Samson, M.K.3    Costanzi, J.J.4    Natale, R.B.5    Feun, L.G.6
  • 16
    • 0025361846 scopus 로고
    • Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells
    • Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH, et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 1990;8:1138-47.
    • (1990) J Clin Oncol , vol.8 , pp. 1138-1147
    • Bar, M.H.1    Sznol, M.2    Atkins, M.B.3    Ciobanu, N.4    Micetich, K.C.5    Boldt, D.H.6
  • 17
  • 18
    • 0025974181 scopus 로고
    • A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma
    • Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, et al. A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991;9:641-48.
    • (1991) J Clin Oncol , vol.9 , pp. 641-648
    • Dutcher, J.P.1    Gaynor, E.R.2    Boldt, D.H.3    Doroshow, J.H.4    Bar, M.H.5    Sznol, M.6
  • 21
    • 0024849183 scopus 로고
    • Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer
    • Rosenberg SA, Lotze MT, Yang JC, Linehan M, Seipp C, Calabro S, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
    • (1989) J Clin Oncol , vol.7 , pp. 1863-1874
    • Rosenberg, S.A.1    Lotze, M.T.2    Yang, J.C.3    Linehan, M.4    Seipp, C.5    Calabro, S.6
  • 23
    • 0026734180 scopus 로고
    • Sequential chemoimmunotherapy in the treatment of metastatic melanoma
    • Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-43.
    • (1992) J Clin Oncol , vol.10 , pp. 1338-1343
    • Richards, J.M.1    Mehta, N.2    Ramming, K.3    Skosey, P.4
  • 24
    • 0027486041 scopus 로고
    • Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma
    • Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-80.
    • (1993) J Clin Oncol , vol.11 , pp. 2173-2180
    • Khayat, D.1    Borel, C.2    Tourani, J.M.3    Benhammouda, A.4    Antoine, E.5    Rixe, O.6
  • 25
    • 0027723618 scopus 로고
    • Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma
    • Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993; 20:27-32.
    • (1993) Semin Oncol , vol.20 , pp. 27-32
    • Legha, S.S.1    Buzaid, A.C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.